alpha-L-Fuc-(1->2)-[alpha-D-Gal-(1->3)]-beta-D-Gal : A branched trisaccharide consisting of beta-D-galactose having an alpha-L-fucosyl residue at the 2-position and an alpha-D-galactosyl residue at the 3-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 49852447 |
| CHEBI ID | 61010 |
| MeSH ID | M0360583 |
| Synonym |
|---|
| alpha-l-fucopyranosyl-(1->2)-[alpha-d-galactopyranosyl-(1->3)]-beta-d-galactopyranose |
| alpha-l-fucosyl-(1->2)-[alpha-d-galactosyl-(1->3)]-beta-d-galactose |
| gala1-3(fuca1-2)galb |
| b antigen trisaccharide |
| alpha-l-fuc-(1->2)-[alpha-d-gal-(1->3)]-beta-d-gal |
| blood group b epitope |
| blood group b antigen epitope |
| CHEBI:61010 , |
| galalpha1,3(fucalpha1,2)galbeta |
| alpha-d-gal-(1->3)-[alpha-l-fuc-(1->2)]-beta-d-gal |
| alphagal1->3(alphafuc1->2)betagal |
| alpha-d-galp-(1->3)-[alpha-l-fucp-(1->2)]-beta-d-galp |
| alpha-d-galactosyl-(1->3)-[alpha-l-fucosyl-(1->2)]-beta-d-galactose |
| alpha-l-fucp-(1->2)-[alpha-d-galp-(1->3)]-beta-d-galp |
| 6-deoxy-alpha-l-galactopyranosyl-(1->2)-[alpha-d-galactopyranosyl-(1->3)]-beta-d-galactopyranose |
| galalpha1-3(fucalpha1-2)galbeta |
| blood group b trisaccharide |
| EPITOPE ID:140125 |
| Q27130562 |
| (2s,3s,4r,5s,6s)-2-{[(2r,3r,4s,5s,6r)-2,5-dihydroxy-6-(hydroxymethyl)-4-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol |
| Role | Description |
|---|---|
| epitope | The biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| alpha-L-Fucp-(1->2)-[alpha-D-Galp-(1->3)]-D-Galp | An L-Fucp-(1->2)-[D-Galp-(1->3)]-D-Galp in which the both the L-fucosyl group at position 2 and the D-galactosyl groups at position 3 have alpha- configuration. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (78.57) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.65) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 5 (35.71%) | 6.00% |
| Case Studies | 2 (14.29%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (50.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||